Unicycive Therapeutics (UNCY) Non Operating Income (2020 - 2026)
Unicycive Therapeutics posted quarterly Non Operating Income of -$4.4 million for Q1 2026, down 151.24% year-on-year from $8.6 million in Q1 2025, and up 41.08% on a QoQ basis from -$7.4 million in Q4 2025.
Unicycive Therapeutics (UNCY) has 7 years of Non Operating Income data on file, last reported at -$4.4 million in Q1 2026.
- For the quarter ending Q1 2026, Non Operating Income fell 151.24% year-over-year to -$4.4 million; the trailing twelve-month figure through Mar 2026 stood at -$10.0 million (down 163.56% YoY), and the FY2025 full-year result was $3.0 million, up 164.22% from the prior year.
- Non Operating Income for Q1 2026 stood at -$4.4 million, up from -$7.4 million in the prior quarter.
- Across five years, Non Operating Income topped out at $17.3 million in Q2 2024 and bottomed at -$12.3 million in Q4 2024.
- The 5-year median for Non Operating Income is -$3000.0 (2022), against an average of -$1.1 million.
- Peak annual rise in Non Operating Income reached 53600.0% in 2023, while the deepest fall reached 49400.0% in 2023.
- A 5-year view of Non Operating Income shows it stood at -$3000.0 in 2022, then tumbled by 49400.0% to -$1.5 million in 2023, then tumbled by 725.86% to -$12.3 million in 2024, then soared by 39.3% to -$7.4 million in 2025, then soared by 41.08% to -$4.4 million in 2026.
- The last three Non Operating Income figures came in at -$4.4 million (Q1 2026), -$7.4 million (Q4 2025), and $1.3 million (Q3 2025), per Business Quant data.
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Non Op. Inc. (Qtr) |
|---|---|---|---|---|---|
| 1 | Quantum Biopharma | 961,148.99 Bn | 961,148.98 Bn | - | - |
| 2 | Alterity Therapeutics | 744,933.29 Bn | 744,933.26 Bn | - | - |
| 3 | Legend Biotech | 2,540.00 Bn | 2,539.71 Bn | 242.10 Mn | - |
| 4 | Nanobiotix | 2,199.85 Bn | 2,199.78 Bn | - | - |
| 5 | Akari Therapeutics | 1,635.88 Bn | 1,635.88 Bn | - | 444,000.00 |
| 6 | Vertex Pharmaceuticals | 111.32 Bn | 104.07 Bn | 2.59 Bn | - |
| 7 | Evaxion A | 62.56 Bn | 62.54 Bn | - | - |
| 8 | Regeneron Pharmaceuticals | 62.55 Bn | 53.79 Bn | 3.31 Bn | 201.20 Mn |
| 9 | Alnylam Pharmaceuticals | 39.57 Bn | 36.56 Bn | 959.66 Mn | -46.98 Mn |
| 10 | Unicycive Therapeutics | 181.94 Mn | 127.36 Mn | - | -4.39 Mn |
Historic Data
Download Data| Date | Value |
|---|---|
| Mar 31, 2026 | -4.39 Mn |
| Dec 31, 2025 | -7.44 Mn |
| Sep 30, 2025 | 1.33 Mn |
| Jun 30, 2025 | 516,000.00 |
| Mar 31, 2025 | 8.56 Mn |
| Dec 31, 2024 | -12.26 Mn |
| Sep 30, 2024 | 2.16 Mn |
| Jun 30, 2024 | 17.26 Mn |
| Mar 31, 2024 | -11.76 Mn |
| Dec 31, 2023 | -1.49 Mn |
| Sep 30, 2023 | 1.61 Mn |
| Jun 30, 2023 | 484,000.00 |
| Mar 31, 2023 | -10.37 Mn |
| Dec 31, 2022 | -3,000.00 |
| Sep 30, 2022 | -3,000.00 |
| Sep 30, 2021 | -486,000.00 |
| Jun 30, 2021 | -321,000.00 |
| Mar 31, 2021 | -233,000.00 |
| Dec 31, 2020 | -163,000.00 |
| Sep 30, 2020 | -76,000.00 |
| Jun 30, 2020 | -2,000.00 |